BioSpace News Archive

Adverum Biotechnologies, Inc. announced nonclinical data supporting the two doses of ixoberogene soroparvovec being evaluated in the Phase 2 LUNA trial and the potential for staggered, bilateral administration in the treatment of wet AMD.

Apellis Pharmaceuticals, Inc. announced post hoc analyses from the 24-month, Phase 3 OAKS and DERBY studies evaluating SYFOVRE™ for the treatment of geographic atrophy secondary to age-related macular degeneration.

SCG Cell Therapy Pte Ltd announced that late-breaking data from the company’s TCR-T therapy pipeline – SCG101, will be presented at the International Society for Cell & Gene Therapy in Paris, France on 1 June.

Bridge Biotherapeutics announced that it received notice from the U.S. Food and Drug Administration that it may proceed with the first-in-human study of BBT-207, which has the potential to be a mutant selective and broad-spectrum fourth-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor for the treatment of non-small cell lung cancer.

Life Biosciences announced preclinical data in nonhuman primates for its novel gene therapy candidate which uses a partial epigenetic reprogramming approach to restore visual function.

Everest Medicines announced that Nefecon, the first-in-disease treatment for primary immunoglobulin A nephropathy, has been approved by the Hainan Medical Products Administration for clinical use in Shanghai Ruijin Hospital’s Hainan subsidiary.

Pharma Two B, a private, venture-backed, late-stage pharmaceutical company, announced that additional results from the Phase 3 pivotal clinical trial evaluating P2B001, will be presented at the 2023 American Academy of Neurology Annual Meeting, April 22-27 in Boston, MA.

IDEAYA Biosciences, Inc. announced further interim results from its Phase 2 clinical trial evaluating darovasertib and crizotinib combination in metastatic uveal melanoma patients.

Belief BioMed Group announced the completion of patient dosing in its Phase III Registrational Clinical Trial of BBM-H901, a gene therapy for Hemophilia B developed and manufactured in-house by Shanghai Belief-Delivery Biomed Co., Ltd., its wholly owned subsidiary.